REGISTER HERE

Register Here Mr. Funtleyder has a 20-year track record of healthcare investing and is currently a Healthcare Portfolio Manager at E Squared Capital Management where he is responsible for conducting fundamental and valuation analysis of public and private companies within the healthcare industry. While at E squared Les has had five IPO exits including serving as CFO of one of the portfolio companies. Prior to E Squared, Mr. Funtleyder was the Director of Strategic Investments and Communications for Opko Health. In this role he participated in over $2 billion in transactions including acquisitions, strategic investments, and licensing deals. He [...]

REGISTER NOW Nikhil Mutyal, Ph.D. is Executive Director, Business Development and Licensing in Pacific Hub for Merck and Co (known as MSD outside of United States) based in San Francisco. Dr. Mutyal leads BD&L efforts for Oncology, Neuroscience and Cardiometabolic diseases for therapeutic opportunities from companies and research initutes based in Western US/CAN, SE Asia, ANZ. Dr. Mutyal’s professional career spans across management consulting for pharma/biotech and BD roles across various companies. Dr. Mutyal received his Ph.D. in Biomedical Engineering (Cancer Research) from Northwestern University and has B.S.+M.S. in Medicinal Chemistry from Indian Institute of Technology, [...]

Register Now Dr. Chris Sheldon is among the best biopharma dealmakers, and his impressive track record includes AstraZeneca/Daiichi's ~$13bn partnership of DS8201 and Dato-Dxd, AstraZeneca's $6.4b acquisition of Acerta over its Acalabrutinib, which is included in the sensation book "In Blood and Money", during his time at AstraZeneca as the head of Oncology BD. Shortly after he took the helm of the GSK's BD, he led the $2B acquisition of Bellus Health and also closed the deal with WuXi Biologics over their multiple bi- & multi-specific T cell engagers for oncology.

This event has ended. Please scroll down for the recording. Dr. Pearce started her career in 1997 at Hoffman-LaRoche, then at Merck launching therapeutics in the cardiovascular space. In 2001, Dr. Pearce joined a small CRO, Medpace, as a Clinical Project Manager. She led hundreds of global Phase 1-4 studies in a variety of therapeutic areas, including neurology, diabetes, lipid-lowering, kidney diseases, and obesity. She started the first business development team and marketing teams at Medpace in 2011. In 2013, Dr. Pearce joined Teva as VP, R&D, leading a new division dedicated to evaluating generics for repurposing. One of [...]

REGISTER HERE

REGISTER HERE

REGISTER HERE Speakers Moderator Organizers